Price
$1,200.06+46.00%1Y
1M+4.91%1Y+46.00%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tier9/10
Value33
Quality97
Momentum49
Growth86
P/E (TTM)39.5
Market Cap$979.64B
1Y Return+46.00%
5Y Return+430.55%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $25.24B (+7.00%)
●Other Immunology grew +98.04% YoY●Product And Service Other -44.00% YoY
SegmentLatestQoQYoY
- Cardiometabolic Health$9.92B+11.92%+50.89%
- Mounjaro$4.23B+19.21%+59.34%
- Zepbound$4.13B+15.85%+79.35%
- Collaborationand Other Revenue$1.35B+5.96%+19.43%
- Oncology$1.23B-10.69%+17.40%
- Verzenio$706.0M-19.80%+7.29%
- Immunology$619.0M-19.96%+7.09%
- Trulicity$600.0M-15.12%-22.18%
- Other Oncology$522.0M+5.52%+34.54%
- Jardiance$512.0M+20.70%+65.16%
- Other Cardiometabolic Health$446.0M-27.80%-16.64%
- Taltz$417.0M-28.52%-12.58%
- Neuroscience$293.0M+22.29%+55.03%
- Other Immunology$202.0M+6.32%+98.04%
- Product And Service Other$56.0M--44.00%
- Alimta---
- Baqsimi---
- Basaglar---
- COVID19Antibodies---
- Cialis---
- Cymbalta---
- Cyramza---
- Diabetes And Obesity---
- Diabetes---
- Emgality---
- Erbitux---
- Forteo---
- Humalog---
- Humulin---
- Olumiant---
- Other Diabetes And Obesity---
- Other Diabetes---
- Other Neuroscience---
- Other Product---
- Other Product Total---
- Royalty---
- TYVYT---
- Trajenta BI---
- Trulicity Member---
- Tyvyt---
- Zyprexa---